Details for Patent: 8,092,828
✉ Email this page to a colleague
Which drugs does patent 8,092,828 protect, and when does it expire?
Patent 8,092,828 protects VYXEOS and is included in one NDA.
This patent has twenty-nine patent family members in nineteen countries.
Summary for Patent: 8,092,828
| Title: | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders |
| Abstract: | Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders. |
| Inventor(s): | Louie; Arthur (Princeton, NJ), Swenson; Christine (Princeton Jct, NJ), Mayer; Lawrence (North Vancouver, CA), Janoff; Andrew (Yardley, PA) |
| Assignee: | Celator Pharmaceuticals, Inc. (Princeton, NJ) |
| Application Number: | 12/032,583 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 8,092,828
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | FOR THE TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,092,828
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3300601 | ⤷ Sign Up | 301185 | Netherlands | ⤷ Sign Up |
| European Patent Office | 3300601 | ⤷ Sign Up | CA 2022 00030 | Denmark | ⤷ Sign Up |
| European Patent Office | 3300601 | ⤷ Sign Up | 2022C/528 | Belgium | ⤷ Sign Up |
| European Patent Office | 3300601 | ⤷ Sign Up | LUC00271 | Luxembourg | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
